Get started
Author

Mehmet Bakırtaş

Observed names: Bakirtas, Mehmet, Bakırtaş, Mehmet, M Bakirtaş, M Bakırtas, M Bakırtaş, M. Bakırtas, M. Bakırtaş, Mehmet BAKIRTAŞ, Mehmet Bakirtas, Mehmet Bakirtaş, Mehmet Bakırtas, Mehmet Bakırtaş
Observed institutions: Ministry of Health, Akdeniz University, Ankara Onkoloji Eğitim ve Araştırma Hastanesi, Sağlık Bilimleri Üniversitesi, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara Eğitim ve Araştırma Hastanesi, Eskişehir Osmangazi University
ORCID: 0000-0003-3216-482X
Observed ORCID: 0000-0003-3216-482X
OpenAlex ID: A5086796918
Analysis of pre-chemotherapy WBC, PLT, monocyte, hemoglobin, and MPV levels in acute myeloid leukemia patients with WT1, FLT3, or NPM gene mutations
2020 · Alparslan Merdin, Mehmet Sinan Dal, et al. · Medicine · 12
Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma
2021 · Bahar Uncu Ulu, Tuğçe Nur Yiğenoğlu, et al. · Leukemia Research · 10
The effect of bulky mass on prognosis in diffuse large-B-cell lymphoma: still poor?
2021 · Semih Başcı, Tuğçe Nur Yiğenoğlu, et al. · Leukemia Research · 10
Inferior prognosis in poor mobilizing myeloma patients
2020 · Tuğçe Nur Yiğenoğlu, Semih Başcı, et al. · Transfusion and Apheresis Science · 10
Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience
2020 · Hikmettullah BATGİ, Semih BAŞCI, et al. · TURKISH JOURNAL OF MEDICAL SCIENCES · 8
The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience
2020 · Hikmettullah Batgi, Alparslan Merdin, et al. · Journal of Oncology Pharmacy Practice · 7
Cathepsin B, p53 expression and AgNORs in transitional cell carcinoma.
1998 · I Akpolat, Y S Bariş, et al. · PubMed · 5
Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey
2023 · Mehmet Bakırtaş, Mehmet Sinan Dal, et al. · Journal of Chemotherapy · 4
The effect of serum vitamin B12, folate, ferritin levels and transferrin saturation on stem cell mobilization in allogeneic donors
2020 · Tuğçe Nur Yiğenoğlu, Semih Başcı, et al. · Transfusion and Apheresis Science · 4
The Relationship Between ABO and Rh Blood Groups with Acute Lymphoblastic Leukemia
2020 · Semih Başcı, Tuğçe Nur Yiğenoğlu, et al. · Acta Oncologica Turcica · 4
PDF
Could blood groups have prognostic significance on survival in patients with diffuse large B cell lymphoma?
2022 · Bahar Uncu Ulu, Semih Başcı, et al. · Leukemia Research · 3
Nivolumab as a bridge to allogeneic hematopoietic stem cell transplantation is associated with improved survival.
2022 · D İskender, M K Çakar, et al. · PubMed · 3
Does myeloma genetic have an effect on stem cell mobilization?
2021 · Semih Başcı, Tuğçe Nur Yiğenoğlu, et al. · Transfusion and Apheresis Science · 3
The Outcome of Diffuse Large B Cell Lymphoma Patients in Adolescent and Young Adult Age Group
2020 · Semih Başcı, Mehmet Bakırtaş, et al. · Journal of Adolescent and Young Adult Oncology · 3
Old is bad? The effect of age on peripheral stem cell mobilization and transplantation outcomes
2020 · Semih Başcı, Mehmet Bakırtaş, et al. · Transfusion and Apheresis Science · 3
Prognostic value of neutrophil/lymphocyte ratio, lymphocyte/monocyte ratio, lactate dehydrogenase, and mean platelet volume in the diagnosis of patients with diffuse large B-cell lymphoma
2022 · Mehmet Bakirtas, Semih Basci, et al. · The Egyptian Journal of Haematology · 2
Molecular evaluation of mutations in acute myeloid leukemia patients from Turkey
2021 · Alparslan Merdin, Mehmet Sinan Dal, et al. · Medicine · 2
Blood group A is a negative risk factor for peripheric blood stem cell mobilization in allogeneic donors
2020 · Tuğçe Nur Yigenoğlu, Mehmet Bakırtaş, et al. · Medical Science and Discovery · 2
The effect of high-dose cytarabine followed by autologous hematopoietic stem cell transplantation on the outcome of patients with mantle cell lymphoma
2019 · Merih K Çakar, Emre Tekgündüz, et al. · Journal of Oncology Pharmacy Practice · 2
Real-World Outcomes of Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute and Chronic Graft-Versus-Host Disease: A Multicenter Retrospective Observational Study from Turkey
2026 · Mehmet Bakırtaş, İlhami Berber, et al. · Journal of Clinical Medicine · 1
PDF
Outcomes of Brentuximab Vedotin Monotherapy in Refractory/Relapsed Classical Hodgkin’s Lymphoma: A Multi-Center Retrospective Study on Survival and Safety
2025 · Mehmet Bakirtas, Ipek Yonal Hindilerden, et al. · Indian Journal of Hematology and Blood Transfusion · 1
PDF
Twice or once a day? Filgrastim dosing schedule for peripheral hematopoietic stem cells mobilization
2025 · Mehmet Bakırtaş, Bahar Uncu Ulu, et al. · Hematology Transfusion and Cell Therapy · 1
Febrile neutropenia risk factors in actively treated diffuse large B-cell lymphoma patients
2022 · Mehmet Bakirtas, TuğçeNur Yiğenoğlu, et al. · Iraqi Journal of Hematology · 1
Is classical Hodgkin lymphoma a different disease in the elderly? A single-center retrospective cohort study.
2021 · J Yildiz, B U Ulu, et al. · PubMed · 1
Second allogeneic stem cell transplantation in acute leukemia patients: single-centre experience
2020 · Mehmet Bakırtaş, Tuğçe Nur Yiğenoğlu, et al. · Jurnal Teknologi Laboratorium · 1
PDF
Works count: 76
Citation count: 108
H-index: 6
I10-index: 4
Year
Topic
Type